Cited by 69Cardiac Ischemia and ReperfusionNitric Oxide and Endothelin EffectsNeurological Disorders and Treatments

Luteolinidin Protects the Postischemic Heart through CD38 Inhibition with Preservation of NAD(P)(H)

Open access
Boslett, James, Hemann, Craig, Zhao, Yong Juan, Lee, Hon-Cheung, Zweier, Jay L.·2017·The Journal of Pharmacology and Experimental Therapeutics

Abstract

We recently showed that ischemia/reperfusion (I/R) of the heart causes CD38 activation with resultant depletion of the cardiac NADP(H) pool, which is most marked in the endothelium. This NADP(H) depletion was shown to limit the production of nitric oxide by endothelial nitric oxide synthase (eNOS), which requires NADPH for nitric oxide production, resulting in greatly altered endothelial function. Therefore, intervention with CD38 inhibitors could reverse postischemic eNOS-mediated endothelial dysfunction. Here, we evaluated the potency of the CD38 inhibitor luteolinidin, an anthocyanidin, at blocking CD38 activity and preserving endothelial and myocardial function in the postischemic heart. Initially, we characterized luteolinidin as a CD38 inhibitor in vitro to determine its potency and mechanism of inhibition. We then tested luteolinidin in the ex vivo isolated heart model, where we determined luteolinidin uptake with aqueous and liposomal delivery methods. Optimal delivery methods were then further tested to determine the effect of luteolinidin on postischemic NAD(P)(H) and tetrahydrobiopterin levels. Finally, through nitric oxide synthase-dependent coronary flow and left ventricular functional measurements, we evaluated the efficacy of luteolinidin to protect vascular and contractile function, respectively, after I/R. With enhanced postischemic preservation of NADPH and tetrahydrobiopterin, there was a dose-dependent effect of luteolinidin on increasing recovery of endothelium-dependent vasodilatory function, as well as enhancing the recovery of left ventricular contractile function with increased myocardial salvage. Thus, luteolinidin is a potent CD38 inhibitor that protects the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction.

Integrity signals

Registry

Crossref · 10.1124/jpet.116.239459

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Luteolinidin raises NAD+ levels in mice.

    “Another flavonoid CD38 inhibitor, luteolinidin, boosts NAD+ levels and protects the endothelium and myocardium after myocardial ischaemia in mice228.”
  • Luteolinidin protects the endothelium and heart muscle after myocardial ischaemia in mice.

    “Another flavonoid CD38 inhibitor, luteolinidin, boosts NAD+ levels and protects the endothelium and myocardium after myocardial ischaemia in mice228.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Boslett, J., Hemann, C., Zhao, Y. J., Lee, H.-C., & Zweier, J. L.
Affiliations
Peking University (CN)
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2017-04
Volume
361
Issue
1
Pages
99-108
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2575657372
Cited by
69
References
66
Citations by year
2026: 4 · 2025: 13 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 5 · 2020: 10 · 2019: 3 · 2018: 8 · 2017: 2
FWCI
4.94
Type
journal article
Language
en
Open access
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL135648, R01HL131941)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
luteolinidin, myocardial ischemia-reperfusion injury, endothelial nitric oxide synthase, tetrahydrobiopterin, endothelial dysfunction, nitric oxide, anthocyanidins, liposomal drug delivery, coronary blood flow, left ventricular contractility, myocardial salvage
MeSH terms
Animals, Anthocyanins, Cardiotonic Agents, Dose-Response Relationship, Drug, Humans, Male, Membrane Glycoproteins, NADP, Recombinant Proteins, Myocardial Ischemia, Rats, Sprague-Dawley, Rats, ADP-ribosyl Cyclase 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review